

Metabolismo, Sistemas Modelo y Terapias para la ELA. Tercer Encuentro Internacional de Investigación en ELA en España

Metabolism, Model Systems and Therapies for ALS. Madrid, 2 de julio / July 2 2019

BIO

Abraham Acevedo Arozena

Abraham Acevedo Arozena holds a PhD in Biology by the University of La Laguna (ULL). His postdoctoral training was done in the MRC Mammalian Genetics Unit (MRC-MGU) of Oxford, United Kingdom, under the initial supervision by Steve DM Brown (director of the MRC-MGU) in collaboration with David C Rubinsztein (University of Cambridge), working in several projects focused on Huntington's Disease (HS) pathogenicity.

In 2009 he created his independent research group at MRC-MGU, continuing the work on HD, and with a new focus in the development of new mice models for Amiotrofic Lateral Sclerosis (ALS) and other neuromuscular diseases.

Since 2016, when he come back to the Universitary Hospital of Canary Islands, he is continuing his research lines started in United Kingdom, focused in the pathogenicity of ALS and Fronto Temporal Dementia (FTD), using the mice as a central model to study in depth the molecular mechanisms of the disease. Currently he is member of the Biomedical Technology Institute of the ULL, and Principal Investigator in the CIBERNED network.